BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/7/2017 8:24:12 AM | Browse: 143 | Download: 124
Publication Name World Journal of Clinical Oncology
Manuscript ID 31780
Country of Manuscript Source Spain
2016-12-07 10:46
Peer-Review Started
2016-12-07 13:56
To Make the First Decision
2017-02-15 12:12
Return for Revision
2017-02-20 12:11
2017-02-26 03:33
Second Decision
2017-02-27 14:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-03-13 12:15
Articles in Press
2017-03-13 12:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-03-30 14:44
Publish the Manuscript Online
2017-04-07 08:24
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript Type Editorial
Article Title Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
Manuscript Source Invited Manuscript
All Author List Enrique Grande, Olga Martínez-Sáez, Pablo Gajate Borau and Teresa Alonso-Gordoa
Funding Agency and Grant Number
Correspondence To Enrique Grande, MD, PhD, Medical Oncology Department, Ramón y Cajal University Hospital, Ctra. Colmenar Viejo km 9100, 28034 Madrid, Spain. egrande@oncologiahrc.com
Keywords Axitinib; Everolimus; Cabozantinib; Kidney cancer; Nivolumab; Renal cell; Sequence; Second line; Sorafenib; Tumor-growth rate
Core Tip The landscape of renal cell carcinoma has dramatically changed in the last decade. Today, at least 6 agents are approved after failure with cytokines, sunitinib or pazopanib in first line treatment. Lack of reliable biomarkers to select the best treatment in daily practice is somewhat frustrating. Therefore, our decisions in real practice are based on safety profiles, patient’ co-morbidities and physician experience or preference. Here we debate the pros and cons of the tumor-growth rate as a tool to select second line systemic treatment after failure to a prior tyrosine kinase-inhibitor in patients with advanced renal cell carcinoma.
Publish Date 2017-04-07 08:24
Citation Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017; 8(2): 100-105
Url http://www.wjgnet.com/2218-4333/full/v8/i2/100.htm
DOI http://dx.doi.org/10.5306/wjco.v8.i2.100
Full Article (PDF) WJCO-8-100.pdf
Full Article (Word) WJCO-8-100.doc
Revised Manuscript 31780-Review.docx
Peer-review Report 31780-Peer-review(s).pdf
Answering Reviewers 31780-Answering reviewers.pdf
Scientific Misconduct Check 31780-Scientific misconduct check.pdf
Scientific Editor Work List 31780-Scientific editor work list.pdf
Audio Core Tip 31780-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 31780-Conflict-of-interest statement.pdf
Copyright License Agreement 31780-Copyright assignment.pdf